TITLE

Letter: Breast cancer regression under oestrogen therapy

AUTHOR(S)
Garcia Webb, P; Briggs, M H
PUB. DATE
November 1973
SOURCE
British Medical Journal;11/17/1973, Vol. 4 Issue 5889, p419
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
64108860

 

Related Articles

  • HRT not only remedy, conference told.  // Australian Nursing Journal;Dec97/Jan98, Vol. 5 Issue 6, p14 

    Reports that the hormone replacement therapy is not the only remedy for women with breast cancer. Effect of treating breast cancer on menopause; Development of a drugs that mimics the good effect of oestrogen.

  • Can biological markers improve the management of breast cancer patients?  // British Journal of Cancer;5/15/2000, Vol. 82 Issue 10, p1625 

    Examines whether biological markers improve the management of breast cancer patients. Provision of information related to prognosis for the patient, therapy and biology of breast cancer by biological markers; Role of oestrogen receptor as a marker of breast cancer.

  • Case of Fulminant Colitis After Docetaxel Therapy for Breast Carcinoma in a Patient With Underlying Ulcerative Colitis. Lalos, Alexander T; Bansal, Pardeep; Rishikesh, Ranjitha // American Journal of Gastroenterology;Oct2009, Vol. 104 Issue 10, p2651 

    A letter to the editor is presented in response to articles about the use of docetaxel therapy for breast cancer in patients with underlying ulcerative colitis.

  • NZGG stands by Its HRT guidance. Yeats, Jodi // New Zealand Doctor;7/26/2006, p11 

    This article reports on the decision of the New Zealand Guidelines Group (NZGG) not to revise its guidelines for hormone replacement therapy. The decision was made after a recently published article on the under-prescription of oestrogen-only therapy due to concerns raised by an outdated...

  • COMMENTARY. Thacker, Holly L. // Evidence Based Medicine;Nov2003, p172 

    The article presents the author's perspectives on breast cancer risk in late postmenopausal women using oestrogen plus progestogen hormone therapy (HT).

  • Anti-oestrogen therapy modified risk of melanoma after breast cancer.  // Australian Journal of Pharmacy;Jun2012, Vol. 93 Issue 1105, p85 

    The article informs about cohort studies according to which women diagnosed with breast cancer and receiving anti-oestrogen therapy are at higher risk of melanoma after breast cancer.

  • AROMATASE INHIBITORS FOR BREAST CANCER: LESSONS FROM THE LABORATORY.  // Nature Reviews Cancer;Nov2003, Vol. 3 Issue 11, p821 

    Compares the efficacy of endocrine therapy with tamoxifen and an alternative strategy of oestrogen deprivation in postmenopausal women with aromatase inhibitors in the treatment of breast cancer. Function of tamoxifen; Mechanism of oestrogen deprivation; Classification of aromatase and...

  • Comment on: The prognostic significance of tumour-stroma ratio in oestrogen receptor-positive breast cancer. Mesker, W E; Dekker, T J A; de Kruijf, E M; Engels, C C; van Pelt, G W; Smit, V T H B M; Tollenaar, R A E M // British Journal of Cancer;5/26/2015, Vol. 112 Issue 11, p1832 

    A letter to the editor is presented in response to article about the prognostic importance of tumour-stroma ratio in oestrogen receptor-positive breast cancer.

  • Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. Yongfeng Shang // Nature Reviews Cancer;May2006, Vol. 6 Issue 5, p360 

    Endometrial cancer is the most common gynaecological cancer, and is associated with endometrial hyperplasia, unopposed oestrogen exposure and adjuvant therapy for breast cancer using selective oestrogen-receptor modulators (SERMs), particularly tamoxifen. Oestrogen and SERMs are thought to be...

  • Control of mammary stem cell function by steroid hormone signalling. Asselin-Labat, Marie-Liesse; Vaillant, Fran├žois; Sheridan, Julie M.; Pal, Bhupinder; Di Wu; Simpson, Evan R.; Yasuda, Hisataka; Smyth, Gordon K.; Martin, T. John; Lindeman, Geoffrey J.; Visvader, Jane E. // Nature;6/10/2010, Vol. 465 Issue 7299, p798 

    The ovarian hormones oestrogen and progesterone profoundly influence breast cancer risk, underpinning the benefit of endocrine therapies in the treatment of breast cancer. Modulation of their effects through ovarian ablation or chemoprevention strategies also significantly decreases breast...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics